Notably, PTC596 was shown to be successful in the treatment of acute leukemia in an in vitro study irrespective of p53 mutational status, which could provide highly beneficial in the treatment of salivary gland cancers which typically demonstrate high mutational burden of p53 (124). This evidence concerns the gene TP53 and salivary gland cancer.